yoltx.comCrawled Oct 25, 2026
Yoltech Therapeutics outlines its Expanded Access policy under Section 561A of the Federal Food, Drug, and Cosmetic Act (the Cures Act) for investigational medicines.
Genome Editing Platform
LNP Delivery Platform
Publications
Corporate Culture
Job Opportunites
Team
About YolTech
YolTech Therapeutics develops gene editing medicines and uses a high-throughput evolution platform and an LNP delivery system to treat serious diseases.
YolTech Therapeutics secures **$45 million in Series B funding**, led by AstraZeneca-CICC’s healthcare investment fund. The biotech company, specializing in **in vivo genome editing therapies**, will use the capital to advance its **clinical programs** and expand global operations. The funding underscores growing investor confidence in its pipeline of gene-editing treatments.
Sep 2025PR NewswireNews article
YolTech Therapeutics receives FDA clearance for its Investigational New Drug (IND) application for **YOLT-101**, an in vivo base editing therapy designed to treat **heterozygous familial hypercholesterolemia (HeFH)**. The therapy targets the **PCSK9 gene**, aiming to address a genetic disorder characterized by high cholesterol levels. YolTech, a clinical-stage biotechnology company, now advances toward potential human trials for this genome-editing approach.
Jun 2025PR NewswireNews article
YolTech Therapeutics reports interim clinical data from an investigator-initiated trial of **YOLT-101**, an in-vivo base editing therapy for **heterozygous familial hypercholesterolemia (HeFH)**. The findings, published on **medRxiv**, show early-stage progress in evaluating the therapy’s safety and efficacy. YOLT-101 targets genetic modifications to address the inherited lipid disorder, marking a potential advancement in precision genetic medicine.
Apr 2025BioSpaceNews article
YolTech Therapeutics reports positive clinical trial results for **YOLT-203**, an in vivo gene-editing therapy targeting **primary hyperoxaluria type 1 (PH1)**. Early data from an investigator-initiated trial show strong safety and pharmacodynamic profiles, with potential to normalize uric acid levels in patients. The therapy represents a precision genetic medicine approach for a rare metabolic disorder.
Feb 2025PR NewswireNews article
